Developing biomarkers for early diagnosis of Alzheimer’s disease and ALS
The scope of Alzheimer's
Worldwide, nearly 47 million people have Alzheimer’s or a related dementia. In the United States, 5.3 million people are living with Alzheimer’s. Unless a cure is found, that number will rise to 16 million by 2050.
The challenge of early detection
Alzheimer’s is primarily diagnosed only after outward symptoms appear. To date, no cost-effective, accurate and practical tool exists to enable early diagnosis and treatment in the pre-clinical stage of Alzheimer’s.
Our solution: A blood test kit
NeuroQuest is developing a simple diagnostic blood test for at-risk populations. The test will serve as a surrogate to costly PET scans indicating the possible formation of brain plaques in the pre-clinical stage .